ロード中...
Outcomes of patients with CLL treated with first line idelalisib plus rituximab after cessation of treatment for toxicity
BACKGROUND: More active therapies are needed for older and unfit patients with CLL who are not eligible for chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab. The PI3Kδ inhibitor idelalisib is effective in treatment-naïve and relapsed/refractory patients with CLL as monotherapy and...
保存先:
| 出版年: | Cancer |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5980238/ https://ncbi.nlm.nih.gov/pubmed/27182988 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30069 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|